News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,402 Results
Type
Article (41809)
Company Profile (473)
Press Release (663120)
Section
Business (208495)
Career Advice (2013)
Deals (35970)
Drug Delivery (97)
Drug Development (83401)
Employer Resources (169)
FDA (16357)
Job Trends (15055)
News (352299)
Policy (32999)
Tag
Academia (2619)
Alliances (50780)
Alzheimer's disease (1333)
Approvals (16310)
Artificial intelligence (172)
Bankruptcy (363)
Best Places to Work (11804)
Biotechnology (355)
Breast cancer (209)
Cancer (1559)
Cardiovascular disease (129)
Career advice (1678)
CAR-T (110)
Cell therapy (328)
Clinical research (66687)
Collaboration (593)
Compensation (311)
COVID-19 (2609)
C-suite (138)
Data (1490)
Diabetes (190)
Diagnostics (6253)
Earnings (86248)
Employer resources (147)
Events (113838)
Executive appointments (483)
FDA (17140)
Funding (533)
Gene therapy (234)
GLP-1 (654)
Government (4423)
Healthcare (19067)
Infectious disease (2706)
Inflammatory bowel disease (121)
Interviews (309)
IPO (16667)
Job creations (3696)
Job search strategy (1430)
Layoffs (451)
Legal (7945)
Lung cancer (227)
Manufacturing (222)
Medical device (13379)
Medtech (13384)
Mergers & acquisitions (19550)
Metabolic disorders (517)
Neuroscience (1717)
NextGen: Class of 2025 (6747)
Non-profit (4541)
Northern California (1883)
Obesity (295)
Opinion (204)
Patents (134)
People (57992)
Phase I (20936)
Phase II (29431)
Phase III (21758)
Pipeline (622)
Postmarket research (2599)
Preclinical (8946)
Radiopharmaceuticals (255)
Rare diseases (302)
Real estate (6001)
Regulatory (22230)
Research institute (2407)
Resumes & cover letters (351)
Southern California (1638)
Startups (3751)
United States (17020)
Vaccines (595)
Weight loss (211)
Date
Today (28)
Last 7 days (472)
Last 30 days (1893)
Last 365 days (35907)
2025 (1640)
2024 (36337)
2023 (41016)
2022 (52276)
2021 (56763)
2020 (54923)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (211)
Asia (38790)
Australia (6448)
California (4329)
Canada (1558)
China (367)
Colorado (193)
Connecticut (214)
Europe (84565)
Florida (600)
Georgia (146)
Illinois (428)
Indiana (242)
Maryland (698)
Massachusetts (3405)
Michigan (184)
Minnesota (320)
New Jersey (1203)
New York (1215)
North Carolina (840)
Northern California (1883)
Ohio (154)
Pennsylvania (1006)
South America (1107)
Southern California (1638)
Texas (626)
Utah (121)
Washington State (442)
705,402 Results for "mersana therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
January 13, 2025
·
5 min read
Genetown
Mersana Therapeutics to Present at Upcoming May 2024 Investor Conferences
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences.
May 22, 2024
·
1 min read
Business
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Mersana Therapeutics, Inc. provided a business update and reported financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
8 min read
Business
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
Mersana Therapeutics, Inc. announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024.
May 2, 2024
·
1 min read
Press Releases
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
November 13, 2024
·
9 min read
Press Releases
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
January 13, 2025
·
8 min read
Genetown
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
Mersana Therapeutics, Inc. announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in April 2024.
May 3, 2024
·
1 min read
Press Releases
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
November 6, 2024
·
1 min read
Genetown
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2024
Mersana Therapeutics, Inc. announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in March 2024.
April 4, 2024
·
1 min read
Genetown
Mersana Therapeutics to Present at Upcoming March 2024 Investor Conferences
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at the following upcoming investor conferences.
February 27, 2024
·
1 min read
1 of 70,541
Next
